Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany

References

• Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol 1993; 4:222–30; http://dx.doi.org/10.1097/00013542-199310000-00006
   Google Scholar
• Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Phys 2000; 61:2437-48; PMID:10794584
   PubMed Web of Science ®Google Scholar
• Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Prac 2002; 19:471-5; PMID:12356697; http://dx.doi.org/10.1093/fampra/19.5.471
   PubMed Web of Science ®Google Scholar
• Hope-Simpson RE. Postherpetic neuralgia. The Jo R Coll Gen Prac 1975; 25:571-5; PMID:1195231
   PubMedGoogle Scholar
• Oxman M, Levin M, Johnson G, Schmader K, Straus S, Gelb L, Arbeit R, Simberkoff M, Gershon A, Davis L. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84; PMID:15930418; http://dx.doi.org/10.1056/NEJMoa051016
   PubMed Web of Science ®Google Scholar
• Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, Breuer J. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70:S24-S30; PMID:12627483; http://dx.doi.org/10.1002/jmv.10316
   PubMedGoogle Scholar
• Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain 2007; 128:148-56; PMID:17070998; http://dx.doi.org/10.1016/j.pain.2006.09.021
   PubMed Web of Science ®Google Scholar
• Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007; 44:1280-8; PMID:17443464; http://dx.doi.org/10.1086/514342
   PubMed Web of Science ®Google Scholar
• Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350-4; PMID:12441828; http://dx.doi.org/10.1097/00002508-200211000-00002
   PubMed Web of Science ®Google Scholar
• De Moragas JM, Kierland PR. The outcome of patients with herpes zoster. AMA Arch Derm 1957; 75:193-6; PMID:13393787; http://dx.doi.org/10.1001/archderm.1957.01550140037006
   PubMedGoogle Scholar
• Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Internal Med 1995; 155:1605-9; PMID:7618983; http://dx.doi.org/10.1001/archinte.1995.00430150071008
   PubMed Web of Science ®Google Scholar
• Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004; 39:342-8; PMID:15307000; http://dx.doi.org/10.1086/421942
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005; 6:356-63; PMID:15943957; http://dx.doi.org/10.1016/j.jpain.2005.01.359
   PubMed Web of Science ®Google Scholar
• Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post-herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. J Public Bealth 2012; 20:441-51; PMID:22822293; http://dx.doi.org/10.1007/s10389-011-0481-8
   PubMedGoogle Scholar
• Schmader KE, Levin MJ, Gnann JW, Jr., McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-8; PMID:22291101; http://dx.doi.org/10.1093/cid/cir970
   PubMed Web of Science ®Google Scholar
• Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database System Rev 2014; 2:Cd006866; PMID:24500927
   PubMed Web of Science ®Google Scholar
• Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging 2007; 24:1-19; PMID:17233544; http://dx.doi.org/10.2165/00002512-200724010-00001
   PubMedGoogle Scholar
• Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25:8326-37; PMID:17980938; http://dx.doi.org/10.1016/j.vaccine.2007.09.066
   PubMed Web of Science ®Google Scholar
• Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998; 51:667-76; PMID:9743315; http://dx.doi.org/10.1016/S0895-4356(98)00036-5
   PubMed Web of Science ®Google Scholar
• van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006; 35:132-7; PMID:16431855; http://dx.doi.org/10.1093/ageing/afj048
   PubMed Web of Science ®Google Scholar
• Ultsch B, Köster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 2013; 14:1015-26; http://dx.doi.org/10.1007/s10198-012-0452-1
   PubMed Web of Science ®Google Scholar
• Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Ser Res 2013; 13:359; PMID:24070414; http://dx.doi.org/10.1186/1472-6963-13-359
   PubMed Web of Science ®Google Scholar
• Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine 2012; 30:2795-800; PMID:21964056; http://dx.doi.org/10.1016/j.vaccine.2011.09.079
   PubMed Web of Science ®Google Scholar
• Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econom 2010; 13:537-51; PMID:20707768; http://dx.doi.org/10.3111/13696998.2010.502854
   PubMedGoogle Scholar
• Bresse X, Annemans L, Preaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoeconom Outcomes Res 2013; 13:393-406; PMID:23537397; http://dx.doi.org/10.1586/erp.13.19
   PubMed Web of Science ®Google Scholar
• Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc 2010; 8:7; PMID:20433704; http://dx.doi.org/10.1186/1478-7547-8-7
   PubMedGoogle Scholar
• Li X, Zhang JH, Betts R, Morrison V, Xu R, Itzler R, Acosta C, Dasbach E, Pellissier J, Johnson G, et al. Modeling the Durability of ZOSTAVAX® Vaccine Efficacy in People ≥60 Years of Age. Vaccine [ under review]
   Web of Science ®Google Scholar
• Hillebrand K. Preliminary data from the BIPS report. 2013.
   Google Scholar
• Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, Camden S, Mansi JA. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010a; 26:656-66.
   PubMed Web of Science ®Google Scholar
• Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta C. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: A Critical Review. Vaccine 2014; 26:1645-53; http://dx.doi.org/10.1016/j.vaccine.2014.01.058
   Web of Science ®Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. PharmacoEconom 2013; 31:125-36; PMID:23335045; http://dx.doi.org/10.1007/s40273-012-0020-7
   PubMed Web of Science ®Google Scholar
• de Boer P, Wilschut J, Postma M. Cost-effectiveness of vaccination against herpes zoster: a review. Hum Vaccines Immunother 2014; 10:2048-61; PMID:25424815; http://dx.doi.org/10.4161/hv.28670
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27:1454-67; PMID:19135492; http://dx.doi.org/10.1016/j.vaccine.2008.12.024
   PubMed Web of Science ®Google Scholar
• de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 2013; 31:1276-83; PMID:23306360; http://dx.doi.org/10.1016/j.vaccine.2012.12.067
   PubMed Web of Science ®Google Scholar
• Brisson M, Pellissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Human vaccines 2008; 4:238-45; PMID:18382137; http://dx.doi.org/10.4161/hv.4.3.5686
   PubMed Web of Science ®Google Scholar
• The Information System of the Federal Health Monitoring. [Members and co-insured familiy members in the SHI on 1st of June each year (number)]. Mitglieder und mitversicherte Familienangehörige der gesetzlichen Krankenversicherung am 1.7. eines Jahres (Anzahl). 2013.
   Google Scholar
• Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis 2011; 11:173; PMID:21679419; http://dx.doi.org/10.1186/1471-2334-11-173
   PubMed Web of Science ®Google Scholar
• Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis 2012; 206:190-6; PMID:22669900; http://dx.doi.org/10.1093/infdis/jis334
   PubMed Web of Science ®Google Scholar
• Weinke T, Edte A, Schmitt S, Lukas K. Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey. J Public Health 2010; 18:367-74; PMID:21124645; http://dx.doi.org/10.1007/s10389-010-0323-0
   PubMedGoogle Scholar
• Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010b; 11:1211-21; http://dx.doi.org/10.1016/j.jpain.2010.02.020
   PubMed Web of Science ®Google Scholar
• German Federal Statistical Office. [A1 Total population. Population of 31. December 2011 by year of age and birth]. Bevölkerung insgesamt. A1 Bevölkerung am 31.12.2011 nach Alters- und Geburtsjahren. 2013.
   Google Scholar
• German Federal Statistical Office. [Population and Emplyoment, Mortality Table Germany 2009/2011]. Bevölkerung und Erwerbstätigkeit, Sterbetafel Deutschland 2009/2011. 2013.
   Google Scholar
• European Medicines Agency. 06/05/2014 Zostavax -EMEA/H/C/000674 -IG/0435. Annex I Summary of Product Characteristics. 2014.
   Google Scholar
• Blank PR, Schwenkglenks M, Szucs TD. Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons. BMC Public Health 2008; 8:272; PMID:18673545; http://dx.doi.org/10.1186/1471-2458-8-272
   PubMed Web of Science ®Google Scholar
• Mereckiene J, Cotter S, D'Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, Lopalco PL, Weber JT, Johansen K, Dematte L, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro surveillance: European communicable disease bulletin 2010; 15.
   Google Scholar
• Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health 2008; 99:383-6; PMID:19009921
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001; 19:3076-90; PMID:11312002; http://dx.doi.org/10.1016/S0264-410X(01)00044-5
   PubMed Web of Science ®Google Scholar
• German Federal Statistical Office. [Gesamtwirtschaft und Umwelt -Verbraucherpreisindizes]. In: Destatis, ed., 2013.
   Google Scholar
• Saxony Association of Statutory Health Insurance Physicians. [Appendix 1 for Vaccination Agreement - obligat services]. Anhang 1 der Impfvereinbarung - Pflichtleistungen. 2013
   Google Scholar
• Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26:277-89; discussion 91-3; PMID:12637076; http://dx.doi.org/10.1016/S1386-6532(03)00005-2
   PubMed Web of Science ®Google Scholar
• AWMF, Arbeitsgemeinschaft der wissenschaftlichen Medizinischen Fachgesellschaften. [Zoster and Zoster pain]. Zoster und Zosterschmerzen. 2005.
   Google Scholar
• Cebrian-Cuenca AM, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis 2011; 11:302; PMID:22044665; http://dx.doi.org/10.1186/1471-2334-11-302
   PubMed Web of Science ®Google Scholar
• National Association of Statutory Health Insurance Physicians and the regional Associations of Statutory Health Insurance Physicians. [Doctors' Fee Scale within the Statutory Health Insurance Scheme]. Einheitlicher Bewertungsmaßstab. http://www.kbv.de/html/arztgruppen_ebm.php, 2013
   Google Scholar
• German Federal Statistical Office. [Statistical yearbook. Germany and international]. Statistisches Jahrbuch. Deutschland und Internationales. 2012.
   Google Scholar
• Institute for Quality and Efficiency in Health Care. [General methods for evaluation of relation between benefit and cost]. Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten. 2009; Version 1.0 vom 12.10.2009:36.
   Google Scholar
• Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, Chosidow O, Blanchon T, Hanslik T. Herpes zoster: Burden of disease in France. Vaccine 2010; 28:7933-8; PMID:20946861; http://dx.doi.org/10.1016/j.vaccine.2010.09.074
   PubMedGoogle Scholar
• Merck Sharp & Dohme Corp. ZOSTAVAX - Highlights of prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. 2014
   Google Scholar
• Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, Fournier SO, Mansi JA, Brisson M. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine 2012; 30:2047-50; PMID:22285632; http://dx.doi.org/10.1016/j.vaccine.2012.01.045
   PubMed Web of Science ®Google Scholar